U.S. Cycling Athlete John Gleaves Accepts Sanction for Anti-Doping Rule Violation

Press Release

23rd March 2020

USADA announced today that John Gleaves, of Fullerton, Calif., an athlete in the sport of cycling, has accepted a four-year suspension for an anti-doping rule violation.
 
Gleaves, 36, tested positive for oxandrolone metabolites 17α-Hydroxymethyl-17β-methyl-18-nor-2-oxa-5α-androst-13-en-3-one and 17β-Hydroxymethyl-17α-methyl-18-nor-2-oxa-5α-androst-13-en-3-one, as well as clomiphene and its metabolite 4-hydroxyclomiphene, as the result of a urine sample collected in-competition at the Masters Track National Championships on August 31, 2019.
 
Oxandrolone is a non-Specified Substance in the class of Anabolic Agents and clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators. Both substances are prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policies, and the International Cycling Union Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.
 
Gleaves accepted a four-year period of ineligibility that began on August 31, 2019, the date his positive sample was collected. In addition, Gleaves has been disqualified from competitive results obtained on and subsequent to August 31, 2019, including forfeiture of any medals, points and prizes.

Views

737

Copyright © LawInSport Limited 2010 - 2020. These pages contain general information only. Nothing in these pages constitutes legal advice. You should consult a suitably qualified lawyer on any specific legal problem or matter. The information provided here was accurate as of the day it was posted; however, the law may have changed since that date. This information is not intended to be, and should not be used as, a substitute for taking legal advice in any specific situation. LawInSport is not responsible for any actions taken or not taken on the basis of this information. Please refer to the full terms and conditions on our website.